Role of 18 F 2-fluoro-2-deoxyglucose Positron Emission Tomography in Upper Gastrointestinal Malignancies

Hye-Won Yun; Ki-Nam Shim

doi:10.4166/kjg.2013.61.6.303

Journal List > Korean J Gastroenterol > v.61(6) > 1007096

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Yun and Shim: Role of 18 F 2-fluoro-2-deoxyglucose Positron Emission Tomography in Upper Gastrointestinal Malignancies

Review Article

Korean J Gastroenterol 2013;61(6):303-306.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.61.6.303

Role of ¹⁸ F 2-fluoro-2-deoxyglucose Positron Emission Tomography in Upper Gastrointestinal Malignancies

Hye-Won Yun, Ki-Nam Shim

Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea

Correspondence to: Ki-Nam Shim, Department of Internal Medicine, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, Korea. Tel: +82-2-2650-2632, Fax: +82-2-2655-2076, E-mail: shimkn@ewha.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The ¹⁸ F 2-fluoro-2-deoxyglucose (FDG) PET/CT scan is an imaging modality used in the management of patients with various types of malignancies. ¹⁸ F-FDG PET/CT has demonstrated significant efficacy in the staging and detection of metastatic disease in malignancies of the gastrointestinal tract. The assessment of the metabolic response to chemotherapy and improvements of overall survivals in malignancies of esophagus and stomach has been demonstrated in several studies. This review focuses on the role of ¹⁸ F-FDG PET/CT scan in staging, metastasis, predict of recurrence and assessment of metabolic response in malignancies of the upper gastrointestinal tract.

Keywords: Positron emission tomography and computed tomography, Upper gastrointestinal tract, Esophageal cancer, Stomach cancer

References

1. Otto W, Frank D. Kraiser-Whilhelm-Institut fur Biologie. The metabolism of tumours. London: Constable;1930.

2. Saga T, Nakamoto Y, Higashi T, Yoshikawa K. Positron emission tomography for the diagnosis and management of patients with gastrointestinal malignancies. Gastrointest Endosc Clin N Am. 2008; 18:479–493.

3. Smyth EC, Shah MA. Role of 18F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol. 2011; 17:5059–5074.

4. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000; 18:3202–3210.

5. Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005; 103:148–156.

6. Kneist W, Schreckenberger M, Bartenstein P, Grünwald F, Oberholzer K, Junginger T. Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg. 2003; 27:1105–1112.

7. Lowe VJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005; 7:422–430.

8. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004; 22:3805–3812.

9. Guo H, Zhu H, Xi Y, et al. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med. 2007; 48:1251–1258.

10. Teyton P, Metges JP, Atmani A, et al. Use of positron emission tomography in surgery follow-up of esophageal cancer. J Gastrointest Surg. 2009; 13:451–458.

11. Weber WA, Ott K, Becker K, et al. Prediction of response to pre-operative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19:3058–3065.

12. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006; 24:4692–4698.

13. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8:797–805.

14. Kameyama R, Yamamoto Y, Izuishi K, et al. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2009; 36:382–388.

15. Herrmann K, Ott K, Buck AK, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med. 2001; 48:1945–1950.

16. Kim SK, Kang KW, Lee JS, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006; 33:148–155.

17. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F–2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004; 28:247–253.

18. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006; 9:192–196.

19. Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005; 103:2383–2390.

20. Yun M, Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med. 2005; 46:1582–1588.

21. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30:288–295.

22. Yeung HW, Macapinlac H, Karpeh M, Finn RD, Larson SM. Accuracy of FDG-PET in gastric cancer. Preliminary experience. Clin Positron Imaging. 1998; 1:213–221.

23. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003; 44:690–699.

24. Tian J, Chen L, Wei B, et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. Nucl Med Commun. 2004; 25:825–831.

25. Yang QM, Kawamura T, Itoh H, et al. Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology. 2008; 55:782–785.

26. Lim JS, Kim MJ, Yun MJ, et al. Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol. 2006; 7:249–256.

27. Sim SH, Kim YJ, Oh DY, et al. The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer. 2009; 9:73.

28. Patriti A, Graziosi L, Baffa N, et al. Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG- PET/TC. Ann Ital Chir. 2007; 78:481–485.

29. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol. 2003; 58:215–221.

30. Di Fabio F, Pinto C, Rojas Llimpe FL, et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gas-triadenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer. 2007; 10:221–227.

TOOLS

Similar articles